A key aspect of the mTORi/HDACi combination is its ability to decrease MYC protein stability; however, in some myeloma cell lines, we have observed a “compensatory” MYC mRNA increase with combination treatment, although the steady-state protein level is decreased[19,20]. Here, MYC is linked to plasma cell myeloma.